Episode Details
Back to Episodes
New Audio Updates: CCO Independent Conference Coverage of Hepatitis B at AASLD 2023
Episode 373
Published 2 years, 1 month ago
Description
In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:
- Current therapies
- Studies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDF
- Kaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis B
- Early vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV Transmission
- Investigational functional cure strategies
- B-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV Infection
- MARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV Infection
- REEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHB
- HBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV Infection
- CVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection
Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
Link to full program:
https://bit.ly/47XJlU4
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.